Brief: Portage Biotech Collaborates With Merck To Study 2 Next-Gen Adenosine Antagonists In Combination With Keytruda In Solid Tumors
05/09/2023 13:22
Sept 5 (Reuters) - Merck & Co Inc MRK.N :
* PORTAGE BIOTECH ANNOUNCES COLLABORATION WITH MERCK TO
EVALUATE
TWO NEXT-GENERATION ADENOSINE ANTAGONISTS IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB) IN SOLID TUMORS
* PORTAGE BIOTECH INC - UNDER TERMS OF AGREEMENT, MERCK WILL
PROVIDE KEYTRUDA FOR PORTAGE BIOTECH'S ADPORT-601
Source text for Eikon: ID:nGNX8wNyfG
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsBrief: Alpha Compute Corp. Provides Mid-Q2 2026 Update
Brief: Alpha Compute Ai Gpu Launch Update First Large-Scale Nvidia Blackwell Cluster
Brief: Alpha Compute Appoints Tom Richer To Advisory Board To Accelerate Ai Gpu Compute Infrastructure And Confidential Cloud Strategy
Brief: Alphaton Capital Rebrands As Alpha Compute Corp. To Reflect Its Growing Ai Compute Business
Brief: Alphaton Capital Announces $43 Million Ai Infrastructure And Financing Partnership With Vertical Data